Home » Clinical Trials » Leukemia » NCT06492304
NCT06492304

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Study Summary

This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies

Want to learn more about this trial?

Request More Info

Interventions

CTX131BIOLOGICAL
CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components

Study Locations

FacilityCityStateCountry
Research Site 6PhoenixArizonaUnited States
Research Site 5StanfordCaliforniaUnited States
Research Site 3BostonMassachusettsUnited States
Research Site 4New YorkNew YorkUnited States
Research Site 2The BronxNew YorkUnited States
Research Site 1HoustonTexasUnited States
Research Site 7East MelbourneVictoriaAustralia

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026